What Transformation Has the Age-Related Macular Degeneration Market Undergone?
The age-related macular degeneration market has seen considerable growth due to a variety of factors.
•The market size for age-related macular degeneration has seen substantial growth in the past few years. There is projected growth from $9.96 billion in 2024 to $10.7 billion in 2025, following a compound annual growth rate (CAGR) of 7.5%.
Factors contributing to this progressive growth during the historic period include demographic changes related to an aging population, lifestyle adaptations, genetic susceptibility, a rise in awareness and early detection, as well as advancements in diagnostic methods.
How Will The Age-Related Macular Degeneration Market Size Evolve In The Foreseeable Future?
The age-related macular degeneration market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for age-related macular degeneration (AMD) is projected to demonstrate substantial expansion in the upcoming years, reaching a value of "$14.38 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%.
This projected expansion during the forecast period is mainly due to advances in genetic and biomarker research, the development of new therapeutic methods, the rise of telemedicine and remote patient monitoring, as well as efforts in patient advocacy and education. Foreseen trends for this period include a focus on personalized medicine, breakthroughs in retinal imaging technologies, the development of lasting drug delivery systems, clinical trials for experimental therapies, and partnerships in research and development.
Which Drivers Are Accelerating Growth In The Age-Related Macular Degeneration Market?
The anticipated escalation in the prevalence of age-related macular degeneration (AMD) is projected to spur the expansion of the AMD market. AMD is a deteriorating eye condition that afflicts the macula, a tiny segment of the retina responsible for central sight. The treatments for AMD aid patients with retinal disorders by lessening the harshness of the disease. For example, Optimaxa, a laser eye treatment specialist based in the UK, reported in February 2023 that AMD influenced 196 million people around the globe. This figure is predicted to hit 288 million by 2040, representing 8.7 percent of the global population. Accordingly, the escalating prevalence of AMD is fueling the growth of the AMD market.
What Are The Core Segments Of The Global Age-Related Macular Degeneration Market?
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Products
3) By Route Of Administration: Intravenous, Intravitreal
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
Pre-Book The Age-Related Macular Degeneration Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Age-Related Macular Degeneration Market Size?
Big players in the age-related macular degeneration (AMD) market are focusing on the development of new-age treatments, such as bispecific antibodies, to minimize the frequency of treatments. A bispecific antibody is a laboratory-created antibody that can bind to two disparate antigens at the same time. For example, the Japan-based pharma company, Chugai Pharmaceutical Co., Ltd., introduced Vabysmo, a bispecific antibody-based intravitreal injection with a capacity of 120 mg/mL, in May 2022. It is intended to address eye disorders such as age-related macular degeneration (AMD) and diabetic macular edema (DME). The innovative therapy works by simultaneously focusing on two critical pathways: angiopoietin-2 (Ang-2), linked to abnormal blood vessel growth and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), a primary factor triggering the creation of new blood vessels which can cause vision weakening. The prolonged dosing intervals of Vabysmo is a significant advantage as it allows for treatments every 16 weeks, thereby improving patient convenience and treatment compliance. With its two-pronged approach, this medical advancement signifies a considerable leap in ophthalmic treatments, effectively serving the immediate need for efficient therapies for retinal ailments.
Who Are the Key Players in the Age-Related Macular Degeneration Market?
Major companies operating in the age-related macular degeneration market include:
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Amgen Inc.
• Alimera Sciences Inc.
• Alkeus Pharmaceuticals Inc.
• AbbVie Inc.
• Outlook Therapeutics Inc.
• Biogen Inc.
• Samsung Bioepis Co. Ltd.
• Biocon Ltd.
• Bio-Thera Biopharmaceutical Co. Ltd.
• AstraZeneca plc
• Acucela Inc.
• Ophthotech Corporation
• Kodiak Sciences Inc.
• REGENXBIO Inc.
• Alkahest Inc.
• Opthea Limited
• Apellis Pharmaceuticals Inc.
• Graybug Vision Inc.
• IVERIC bio Inc.
• Santen Pharmaceutical Co. Ltd.
• Ocular Therapeutix Inc.
• Tyrogenex Inc.
• Chengdu Kanghong Pharmaceutical Group Co. Ltd.
• I-Mab Biopharma Co. Ltd.
• pSivida Corp.
• Clearside Biomedical Inc.
• SciFluor Life Sciences LLC
• Lineage Cell Therapeutics Inc.
What are the Regional Insights into the Age-Related Macular Degeneration Market?
North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
